About Torque

Torque is developing a new class of Deep-Primed™ T cell therapeutics to dramatically expand cell therapy cures for cancer.

Our Deep-Priming technology platform uses advanced cell process engineering to:

  1. prime and activate T cells to target multiple tumor antigens, and
  2. tether immune-stimulatory drugs to the surface of these multi-target T cells to direct immune activation in the tumor microenvironment
  3. using a proprietary technology platform, without genetic engineering, for a high margin of safety.

Deep-Primed T cells both target multiple tumor antigens and pharmacologically activate an immune response with anchored cytokines. This process does not require genetic engineering of the T cells and so preserves the natural T cell receptor for delivering a regulated immune response, with the potential for a high margin of safety.

In addition to antigen priming, immunomodulators are tethered to the surface of Deep-Primed T cells—initially IL-15 and IL-12 cytokines, and TLR agonists—that activate both innate and adaptive immunity. Administering these immunomodulators systemically to a patient can cause lethal toxicity by activating immune cells throughout the body. By loading precise doses of cytokines onto the surface of T cells, Deep Priming focuses the immune response to target the tumor, without systemic exposure.

Torque Deep-Primed cell therapeutics have the potential to be foundational therapy for both solid and hematologic tumors, addressing the two fundamental challenges of immunotherapy:

  1. Tumors with heterogeneous antigens that readily develop resistance to single-target therapy
  2. Immunosuppressive tumor microenvironments that limit T cell function, persistence, and trafficking

In hematologic cancers, this new class of immune cell therapeutics has the potential to improve on the initial success of single-target CAR T therapeutics with expanded efficacy, and also move cell therapy treatment out of the hospital with a high margin of safety. For solid tumors, Deep-Primed T cells have the potential to enable efficacy against tumors with heterogeneous antigens protected by hostile microenvironments, which are not readily addressable with the first generation of immune cell therapies.

Torque’s lead product candidate—TRQ-1501 (Deep IL-15 primed T cells)—is in Phase 1/2 clinical trials for solid tumors and hematologic cancers. In preclinical studies, TRQ-1501 demonstrated increased T cell proliferation, engraftment, and tumor cell killing, including the potential to improve on preconditioning regimens.

Back to Top